166 related articles for article (PubMed ID: 38521213)
1. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
De Bondt M; Renders J; Struyf S; Hellings N
Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys SFH; Rip J; Hendriks RW; Corneth OBJ
Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
[TBL] [Abstract][Full Text] [Related]
4. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
5. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
[TBL] [Abstract][Full Text] [Related]
6. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Whang JA; Chang BY
Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Good L; Benner B; Carson WE
Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
[TBL] [Abstract][Full Text] [Related]
10. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
[TBL] [Abstract][Full Text] [Related]
11. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT
J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648
[TBL] [Abstract][Full Text] [Related]
12. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
13. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.
Crofford LJ; Nyhoff LE; Sheehan JH; Kendall PL
Expert Rev Clin Immunol; 2016 Jul; 12(7):763-73. PubMed ID: 26864273
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
[TBL] [Abstract][Full Text] [Related]
15. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Tichenor MS; Wiener JJM; Rao NL; Bacani GM; Wei J; Pooley Deckhut C; Barbay JK; Kreutter KD; Chang L; Clancy KW; Murrey HE; Wang W; Ahn K; Huber M; Rex E; Coe KJ; Wu J; Rui H; Sepassi K; Gaudiano M; Bekkers M; Cornelissen I; Packman K; Seierstad M; Xiouras C; Bembenek SD; Alexander R; Milligan C; Balasubramanian S; Lebsack AD; Venable JD; Philippar U; Edwards JP; Hirst G
J Med Chem; 2022 Nov; 65(21):14326-14336. PubMed ID: 36314537
[TBL] [Abstract][Full Text] [Related]
16. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
17. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
Lin P; Zhang D; Lin J
Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
[TBL] [Abstract][Full Text] [Related]
18. Bruton's Tyrosine Kinase Inhibitors: Recent Updates.
Fares A; Carracedo Uribe C; Martinez D; Rehman T; Silva Rondon C; Sandoval-Sus J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396884
[TBL] [Abstract][Full Text] [Related]
19. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
20. Impaired B Cell Apoptosis Results in Autoimmunity That Is Alleviated by Ablation of Btk.
Wright JA; Bazile C; Clark ES; Carlesso G; Boucher J; Kleiman E; Mahmoud T; Cheng LI; López-Rodríguez DM; Satterthwaite AB; Altman NH; Greidinger EL; Khan WN
Front Immunol; 2021; 12():705307. PubMed ID: 34512628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]